Noor S Sachdev, MD
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 36
- 9 carriers
- Offices
- 4
Offices
4 locations · Bass Medical Group · 292 clinicians in this group
Hospitals listed: El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
36 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sachdev’s office at (408) 358-2663 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
36 of 36 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A104845 · Current
Licensed to practise in California · since 2008 · expires 2028-07-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$243,979
Medicare paid this office $243,979 for 383 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 316 | $100,066 | $161 |
| Botox | 24 | $71,915 | None |
| New patient visit (60+ min) | 133 | $25,398 | $191 |
| Face injection for nerve paralysis | 21 | $11,111 | $198 |
| Return visit (30+ min) | 65 | $8,583 | $99 |
See all 11 services
| Long return visit (40+ min) | 316 | $100,066 | $161 |
| Botox | 24 | $71,915 | None |
| New patient visit (60+ min) | 133 | $25,398 | $191 |
| Face injection for nerve paralysis | 21 | $11,111 | $198 |
| Return visit (30+ min) | 65 | $8,583 | $99 |
| Evaluation of neuropsychological test, first hour | 53 | $6,750 | $121 |
| Administration of psychological or neuropsychological test, first 30 minutes | 96 | $4,026 | $39 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 95 | $3,693 | $36 |
| Nerve test | 13 | $3,025 | $233 |
| Muscle electrical test | 14 | $2,690 | $100 |
| Short return visit (20+ min) | 12 | $728 | $61 |
Who their Medicare patients are
383 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 18% · Women 55% · Also on Medicaid 5% · Health risk score 1.34. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Dementia 45% · Stroke 42% · Coronary heart disease 33% · Diabetes 28% · Atrial fibrillation 21% · Depression 21% · Chronic kidney disease 18% · Cancer 18% · Heart failure 15% · COPD 13%.
The office billed $918,029, Medicare allowed $323,847 and paid $243,979; for 16,259 services of 23 kinds; $71,915 of it was for drugs given in the office and $172,064 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 383 | 16,259 | 77 | 1.34 | $918,029 | $243,979 |
| 2023 | 275 | 14,985 | 77 | 1.22 | $642,403 | $178,968 |
| 2022 | 322 | 23,696 | 77 | 1.29 | $849,934 | $240,547 |
| 2021 | 329 | 24,988 | 77 | 1.32 | $907,432 | $269,159 |
| 2020 | 500 | 27,322 | 77 | 1.49 | $1,142,428 | $331,083 |
| 2019 | 536 | 28,124 | 77 | 1.45 | $709,559 | $310,162 |
| 2018 | 524 | 20,816 | 77 | 1.50 | $503,765 | $266,709 |
| 2017 | 529 | 12,121 | 76 | 1.54 | $399,185 | $208,279 |
| 2016 | 463 | 7,331 | 76 | 1.51 | $382,535 | $202,074 |
| 2015 | 559 | 5,219 | 76 | 1.59 | $440,480 | $227,029 |
| 2014 | 480 | 3,346 | 76 | 1.40 | $369,870 | $201,309 |
| 2013 | 398 | 3,227 | 76 | 1.40 | $273,985 | $151,612 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Botox | 22 | $69,058 | None |
| Long return visit (40+ min) | 198 | $49,447 | $160 |
| New patient visit (60+ min) | 97 | $17,425 | $180 |
| Face injection for nerve paralysis | 14 | $8,418 | $200 |
| Return visit (30+ min) | 55 | $7,915 | $116 |
| Evaluation of neuropsychological test, first hour | 37 | $4,907 | $120 |
| Muscle electrical test | 18 | $4,442 | $101 |
| Nerve test | 15 | $4,284 | $238 |
| Administration of psychological or neuropsychological test, first 30 minutes | 42 | $1,763 | $42 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 42 | $1,656 | $39 |
| Short return visit (20+ min) | 18 | $1,627 | $86 |
2022: 13 services
| Botox | 29 | $111,365 | None |
| Long return visit (40+ min) | 230 | $54,606 | $151 |
| New patient visit (60+ min) | 96 | $17,954 | $187 |
| Face injection for nerve paralysis | 17 | $11,251 | $201 |
| Nerve test | 27 | $7,144 | $255 |
| Muscle electrical test | 27 | $5,883 | $105 |
| Evaluation of neuropsychological test, first hour | 33 | $3,919 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $3,260 | $93 |
| Return visit (30+ min) | 18 | $3,190 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,872 | $179 |
| Muscle electrical test | 12 | $2,260 | $87 |
| Administration of psychological or neuropsychological test, first 30 minutes | 29 | $1,271 | $42 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 29 | $1,164 | $39 |
2021: 14 services
| Botox | 27 | $116,449 | None |
| Long return visit (40+ min) | 209 | $51,192 | $164 |
| New patient visit (60+ min) | 114 | $23,325 | $205 |
| Muscle electrical test | 69 | $15,483 | $105 |
| Nerve test | 44 | $12,097 | $257 |
| Face injection for nerve paralysis | 16 | $9,736 | $199 |
| Critical care, first 30-74 minutes | 17 | $6,114 | $197 |
| Nerve test | 21 | $5,108 | $232 |
| Return visit (30+ min) | 30 | $4,662 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,440 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,394 | $183 |
| Evaluation of neuropsychological test, first hour | 19 | $2,609 | $124 |
| Administration of psychological or neuropsychological test, first 30 minutes | 25 | $1,110 | $44 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 25 | $1,010 | $40 |
2020: 15 services
| Botox | 38 | $123,766 | None |
| Long return visit (40+ min) | 280 | $44,393 | $118 |
| Critical care, first 30-74 minutes | 59 | $38,629 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 88 | $23,058 | $91 |
| New patient visit (60+ min) | 93 | $16,722 | $180 |
| Critical care, each additional 30 minutes | 52 | $15,123 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 73 | $13,598 | $177 |
| Nerve test | 50 | $12,867 | $252 |
| Muscle electrical test | 56 | $12,742 | $96 |
| Face injection for nerve paralysis | 25 | $11,019 | $187 |
| Return visit (30+ min) | 55 | $5,827 | $97 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 12 | $3,360 | $134 |
| Measurement of brain wave activity (eeg), in coma or asleep | 26 | $1,457 | $52 |
| Administration of psychological or neuropsychological test, first 30 minutes | 28 | $845 | $30 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 28 | $802 | $29 |
2019: 15 services
| Botox | 38 | $119,246 | None |
| Long return visit (40+ min) | 303 | $53,345 | $129 |
| Critical care, first 30-74 minutes | 55 | $31,771 | $196 |
| New patient visit (60+ min) | 121 | $22,597 | $187 |
| Critical care, each additional 30 minutes | 41 | $11,206 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $10,555 | $93 |
| Face injection for nerve paralysis | 25 | $9,741 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,904 | $178 |
| Return visit (30+ min) | 66 | $6,460 | $91 |
| Nerve test | 21 | $5,430 | $259 |
| Administration of psychological or neuropsychological test, first 30 minutes | 109 | $4,799 | $44 |
| Administration of psychological or neuropsychological test, each additional 30 minutes | 110 | $4,550 | $41 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 12 | $4,502 | $136 |
| Muscle electrical test | 23 | $4,194 | $95 |
| Measurement of brain wave activity (eeg), in coma or asleep | 13 | $754 | $54 |
2018: 14 services
| Botox | 23 | $85,650 | None |
| Long return visit (40+ min) | 251 | $38,541 | $121 |
| Critical care, first 30-74 minutes | 56 | $30,986 | $184 |
| New patient visit (60+ min) | 119 | $20,526 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $15,682 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 66 | $11,171 | $169 |
| Return visit (30+ min) | 102 | $10,192 | $92 |
| Critical care, each additional 30 minutes | 37 | $8,586 | $92 |
| Nerve test | 26 | $6,326 | $243 |
| Muscle electrical test | 30 | $5,171 | $86 |
| Face injection for nerve paralysis | 15 | $5,016 | $111 |
| Neuropsychological testing by a computer with interpretation and report by a qualified healthcare professional | 107 | $4,710 | $43 |
| Psychological testing with interpretation and report by computer | 109 | $2,508 | $23 |
| Measurement of brain wave activity (eeg), in coma or asleep | 30 | $1,601 | $50 |
2017: 14 services
| Botox | 20 | $49,988 | None |
| Long return visit (40+ min) | 276 | $46,475 | $114 |
| Critical care, first 30-74 minutes | 66 | $27,609 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 115 | $20,640 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $13,848 | $169 |
| New patient visit (60+ min) | 82 | $13,735 | $168 |
| Critical care, each additional 30 minutes | 50 | $10,174 | $92 |
| Return visit (30+ min) | 45 | $4,247 | $94 |
| Nerve test | 16 | $3,768 | $235 |
| Face injection for nerve paralysis | 13 | $3,682 | $112 |
| Neuropsychological testing by a computer with interpretation and report by a qualified healthcare professional | 76 | $3,292 | $43 |
| Muscle electrical test | 16 | $2,602 | $84 |
| Measurement of brain wave activity (eeg), in coma or asleep | 40 | $2,027 | $49 |
| Psychological testing with interpretation and report by computer | 77 | $1,723 | $22 |
2016: 11 services
| Long return visit (40+ min) | 263 | $51,037 | $121 |
| Critical care, first 30-74 minutes | 72 | $32,888 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 100 | $25,345 | $89 |
| New patient visit (60+ min) | 104 | $18,266 | $176 |
| Critical care, each additional 30 minutes | 59 | $14,519 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $10,907 | $173 |
| Nerve test | 16 | $4,113 | $242 |
| Muscle electrical test | 19 | $3,641 | $87 |
| Measurement of brain wave activity (eeg), in coma or asleep | 31 | $1,717 | $51 |
| Neuropsychological testing by a computer with interpretation and report by a qualified healthcare professional | 39 | $1,704 | $44 |
| Psychological testing with interpretation and report by computer | 41 | $950 | $23 |
2015: 12 services
| Critical care, first 30-74 minutes | 85 | $44,291 | $193 |
| Long return visit (40+ min) | 238 | $40,216 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 107 | $25,119 | $92 |
| Critical care, each additional 30 minutes | 69 | $20,906 | $97 |
| New patient visit (60+ min) | 114 | $20,595 | $181 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $15,329 | $178 |
| Neuropsychological testing by a computer with interpretation and report by a qualified healthcare professional | 165 | $7,531 | $45 |
| Return visit (30+ min) | 71 | $7,466 | $93 |
| Nerve test | 23 | $6,212 | $248 |
| Muscle electrical test | 22 | $4,251 | $89 |
| Psychological testing with interpretation and report by computer | 172 | $4,153 | $24 |
| Measurement of brain wave activity (eeg), in coma or asleep | 29 | $1,552 | $52 |
2014: 12 services
| Critical care, first 30-74 minutes | 103 | $53,754 | $195 |
| Long return visit (40+ min) | 198 | $28,995 | $124 |
| New patient visit (60+ min) | 124 | $22,749 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $16,266 | $92 |
| Return visit (30+ min) | 121 | $14,721 | $94 |
| Critical care, each additional 30 minutes | 67 | $12,713 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,612 | $180 |
| Nerve test | 31 | $8,109 | $253 |
| Muscle electrical test | 28 | $5,542 | $89 |
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 13 | $4,694 | $293 |
| New patient visit (45+ min) | 12 | $1,727 | $144 |
| Measurement of brain wave activity (eeg), in coma or asleep | 23 | $1,410 | $52 |
2013: 15 services
| Long return visit (40+ min) | 179 | $29,603 | $118 |
| Critical care, first 30-74 minutes | 46 | $22,550 | $191 |
| New patient visit (60+ min) | 99 | $18,125 | $183 |
| Return visit (30+ min) | 117 | $14,674 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,711 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $7,479 | $90 |
| Monitoring and localization of seizure activity over 24-hour period using portable 16-channel electroencephalograph (EEG) | 12 | $7,022 | $439 |
| Nerve test | 23 | $6,240 | $250 |
| Muscle electrical test | 31 | $5,779 | $84 |
| Measurement of brain wave activity (eeg), digital analysis | 12 | $5,620 | $468 |
| Critical care, each additional 30 minutes | 29 | $3,543 | $96 |
| New patient visit (45+ min) | 21 | $3,103 | $148 |
| New patient visit (30+ min) | 18 | $1,831 | $102 |
| Short return visit (20+ min) | 20 | $1,703 | $65 |
| Measurement of brain wave activity (eeg), in coma or asleep | 24 | $1,318 | $51 |
Drugs they prescribed that Part D paid
$1,513,525
Pharmacies billed $1,513,525 in 2024. Most of that is three immune-globulin drugs at $11,000–$30,000 a fill for a small number of people.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (69 of 1,801) in 2024. A higher opioid share than 9 in 10 peers; the typical neurology clinician is at 0%. Long-acting opioids: 16% of their opioid prescriptions.
1,600 generic and 201 brand-name prescriptions · $1,513,525 in drug cost · 44 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Panzyga | Immune globulin | 18 | $544,141 | $30,230 |
| Privigen | Immune globulin | 19 | $261,489 | $13,763 |
| Gamunex-C | Immune globulin | 12 | $129,015 | $10,751 |
| Nuplazid | Parkinson's psychosis | 11 | $53,758 | $4,887 |
| Aimovig | Migraine | 64 | $48,994 | $766 |
See all 36 drugs
| Panzyga | Immune globulin | 18 | $544,141 | $30,230 |
| Privigen | Immune globulin | 19 | $261,489 | $13,763 |
| Gamunex-C | Immune globulin | 12 | $129,015 | $10,751 |
| Nuplazid | Parkinson's psychosis | 11 | $53,758 | $4,887 |
| Aimovig | Migraine | 64 | $48,994 | $766 |
| Rivastigmine | None | 54 | $13,572 | $251 |
| Rytary | Parkinson's | 12 | $13,242 | $1,104 |
| Lacosamide | None | 48 | $8,893 | $185 |
| Emgality | Migraine | 11 | $7,558 | $687 |
| Memantine | None | 108 | $5,294 | $49 |
| Levetiracetam | None | 106 | $4,925 | $46 |
| Gabapentin | None | 166 | $3,825 | $23 |
| Pyridostigmine | None | 19 | $3,324 | $175 |
| Donepezil | None | 221 | $3,100 | $14 |
| Sumatriptan | None | 68 | $1,961 | $29 |
| Carbidopa-Levodopa | None | 85 | $1,932 | $23 |
| Pregabalin | None | 36 | $1,457 | $40 |
| Propranolol | None | 54 | $1,386 | $26 |
| Escitalopram | None | 75 | $1,160 | $15 |
| Divalproex | None | 30 | $881 | $29 |
| Modafinil | None | 18 | $575 | $32 |
| Primidone | None | 31 | $567 | $18 |
| Amitriptyline | None | 14 | $550 | $39 |
| Quetiapine | None | 17 | $539 | $32 |
| Clonazepam | None | 47 | $517 | $11 |
| Nortriptyline | None | 37 | $474 | $13 |
| Topiramate | None | 21 | $473 | $23 |
| Atorvastatin | None | 17 | $332 | $20 |
| Baclofen | None | 12 | $271 | $23 |
| Tramadol | None | 47 | $268 | $6 |
| Clopidogrel | None | 22 | $222 | $10 |
| Hydrocodone-Acetaminophen | None | 11 | $216 | $20 |
| Methadone | None | 11 | $208 | $19 |
| Risperidone | None | 16 | $117 | $7 |
| Pramipexole Dihydrochloride | None | 11 | $78 | $7 |
| Lorazepam | None | 17 | $19 | $1 |
Year by year
| 2024 | 1,801 | 305 | 4% (69) | 11% | $1,513,525 |
| 2023 | 1,465 | 259 | 3% (47) | 15% | $1,528,395 |
| 2022 | 1,621 | 272 | 2% (34) | 18% | $1,046,174 |
| 2021 | 1,533 | 274 | 3% (42) | 20% | $1,192,348 |
| 2020 | 1,494 | 264 | 3% (42) | None | $818,672 |
| 2019 | 1,521 | 266 | 3% (49) | 20% | $859,376 |
| 2018 | 1,411 | 257 | 2% (34) | 24% | $610,480 |
| 2017 | 1,246 | 190 | None | 32% | $622,227 |
| 2016 | 1,196 | 232 | None | 32% | $423,959 |
| 2015 | 1,170 | 223 | 2% (20) | 34% | $472,073 |
| 2014 | 1,158 | 188 | 2% (22) | 33% | $567,751 |
| 2013 | 1,091 | 173 | 2% (18) | None | $587,470 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 36 drugs
| Panzyga | Immune globulin | 14 | $536,656 | $38,333 |
| Gamunex-C | Immune globulin | 27 | $429,580 | $15,910 |
| Privigen | Immune globulin | 19 | $223,337 | $11,755 |
| Aimovig | Migraine | 39 | $31,241 | $801 |
| Qulipta | None | 13 | $14,742 | $1,134 |
| Namzaric | None | 15 | $13,975 | $932 |
| Lacosamide | None | 58 | $10,249 | $177 |
| Rivastigmine | None | 21 | $9,942 | $473 |
| Emgality | Migraine | 12 | $8,724 | $727 |
| Pregabalin | None | 86 | $4,870 | $57 |
| Levetiracetam | None | 73 | $3,457 | $47 |
| Donepezil | None | 178 | $3,391 | $19 |
| Memantine Hcl Er | None | 13 | $2,911 | $224 |
| Carbidopa-Levodopa | None | 62 | $2,673 | $43 |
| Gabapentin | None | 112 | $2,530 | $23 |
| Pyridostigmine | None | 17 | $2,474 | $146 |
| Memantine | None | 25 | $1,975 | $79 |
| Sumatriptan | None | 27 | $1,507 | $56 |
| Propranolol | None | 46 | $1,494 | $32 |
| Primidone | None | 32 | $1,465 | $46 |
| Escitalopram | None | 65 | $1,237 | $19 |
| Divalproex | None | 18 | $1,179 | $66 |
| Propranolol Hcl Er | None | 19 | $837 | $44 |
| Topiramate | None | 22 | $705 | $32 |
| Baclofen | None | 14 | $473 | $34 |
| Clopidogrel | None | 29 | $471 | $16 |
| Hydrocodone-Acetaminophen | None | 14 | $430 | $31 |
| Atorvastatin | None | 29 | $329 | $11 |
| Clonazepam | None | 35 | $299 | $9 |
| Methadone | None | 12 | $279 | $23 |
| Nortriptyline | None | 15 | $271 | $18 |
| Quetiapine | None | 14 | $253 | $18 |
| Trazodone | None | 16 | $230 | $14 |
| Tramadol | None | 19 | $76 | $4 |
| Lorazepam | None | 11 | $28 | $3 |
| Fluoxetine | None | 12 | $18 | $2 |
2022: 39 drugs
| Gamunex-C | Immune globulin | 29 | $392,841 | $13,546 |
| Privigen | Immune globulin | 12 | $121,140 | $10,095 |
| Avonex | None | 12 | $89,243 | $7,437 |
| Aimovig | Migraine | 51 | $39,543 | $775 |
| Nuedexta | None | 19 | $26,919 | $1,417 |
| Rivastigmine | None | 49 | $19,504 | $398 |
| Namzaric | None | 19 | $17,112 | $901 |
| Rytary | Parkinson's | 18 | $15,122 | $840 |
| Vimpat | None | 13 | $13,233 | $1,018 |
| Emgality | Migraine | 12 | $8,461 | $705 |
| Aspirin-Dipyridamole Er | None | 13 | $7,967 | $613 |
| Lacosamide | None | 24 | $7,231 | $301 |
| Memantine Hcl Er | None | 19 | $7,113 | $374 |
| Pregabalin | None | 100 | $4,702 | $47 |
| Carbidopa-Levodopa | None | 75 | $4,147 | $55 |
| Memantine | None | 46 | $4,040 | $88 |
| Gabapentin | None | 136 | $3,888 | $29 |
| Donepezil | None | 196 | $3,340 | $17 |
| Pyridostigmine | None | 27 | $2,507 | $93 |
| Propranolol | None | 47 | $2,004 | $43 |
| Sumatriptan | None | 34 | $1,670 | $49 |
| Levetiracetam | None | 57 | $1,664 | $29 |
| Escitalopram | None | 49 | $1,557 | $32 |
| Divalproex | None | 25 | $1,089 | $44 |
| Propranolol Hcl Er | None | 18 | $950 | $53 |
| Topiramate | None | 27 | $808 | $30 |
| Primidone | None | 27 | $712 | $26 |
| Baclofen | None | 15 | $677 | $45 |
| Fluoxetine | None | 13 | $614 | $47 |
| Pramipexole Dihydrochloride | None | 22 | $429 | $20 |
| Clopidogrel | None | 21 | $421 | $20 |
| Methadone | None | 11 | $340 | $31 |
| Atorvastatin | None | 35 | $304 | $9 |
| Nortriptyline | None | 24 | $240 | $10 |
| Fludrocortisone Acetate | None | 12 | $220 | $18 |
| Clonazepam | None | 24 | $193 | $8 |
| Hydrocodone-Acetaminophen | None | 13 | $177 | $14 |
| Quetiapine | None | 19 | $103 | $5 |
| Lorazepam | None | 11 | $16 | $1 |
2021: 33 drugs
| Gamunex-C | Immune globulin | 39 | $408,274 | $10,469 |
| Avonex | None | 13 | $90,768 | $6,982 |
| Aimovig | Migraine | 35 | $27,442 | $784 |
| Vimpat | None | 30 | $24,573 | $819 |
| Namzaric | None | 30 | $21,641 | $721 |
| Rivastigmine | None | 39 | $18,211 | $467 |
| Neupro | None | 18 | $16,095 | $894 |
| Emgality | Migraine | 13 | $8,573 | $659 |
| Aspirin-Dipyridamole Er | None | 15 | $6,566 | $438 |
| Memantine Hcl Er | None | 17 | $5,413 | $318 |
| Trintellix | None | 12 | $5,205 | $434 |
| Carbidopa-Levodopa | None | 54 | $4,809 | $89 |
| Donepezil | None | 237 | $4,126 | $17 |
| Gabapentin | None | 141 | $3,569 | $25 |
| Memantine | None | 50 | $3,056 | $61 |
| Sumatriptan | None | 41 | $3,050 | $74 |
| Pyridostigmine | None | 40 | $2,925 | $73 |
| Propranolol | None | 54 | $2,765 | $51 |
| Pregabalin | None | 67 | $2,732 | $41 |
| Levetiracetam | None | 40 | $2,463 | $62 |
| Escitalopram | None | 33 | $1,102 | $33 |
| Pramipexole Dihydrochloride | None | 33 | $1,054 | $32 |
| Topiramate | None | 27 | $778 | $29 |
| Primidone | None | 27 | $726 | $27 |
| Fluoxetine | None | 14 | $661 | $47 |
| Clopidogrel | None | 22 | $529 | $24 |
| Atorvastatin | None | 34 | $442 | $13 |
| Divalproex | None | 19 | $340 | $18 |
| Hydrocodone-Acetaminophen | None | 19 | $287 | $15 |
| Quetiapine | None | 17 | $182 | $11 |
| Methadone | None | 11 | $117 | $11 |
| Clonazepam | None | 14 | $83 | $6 |
| Tramadol | None | 12 | $45 | $4 |
2020: 39 drugs
| Hizentra | Immune globulin | 13 | $205,101 | $15,777 |
| Gamunex-C | Immune globulin | 15 | $189,701 | $12,647 |
| Nuplazid | Parkinson's psychosis | 13 | $47,470 | $3,652 |
| Ampyra | None | 14 | $43,832 | $3,131 |
| Rivastigmine | None | 50 | $25,315 | $506 |
| Namzaric | None | 36 | $24,716 | $687 |
| Aimovig | Migraine | 24 | $17,253 | $719 |
| Neupro | None | 28 | $15,328 | $547 |
| Aspirin-Dipyridamole Er | None | 17 | $10,892 | $641 |
| Memantine Hcl Er | None | 23 | $9,855 | $428 |
| Emgality | Migraine | 13 | $8,242 | $634 |
| Trintellix | None | 15 | $6,074 | $405 |
| Memantine | None | 46 | $4,808 | $105 |
| Tegretol Xr | None | 12 | $4,035 | $336 |
| Donepezil | None | 244 | $3,723 | $15 |
| Carbidopa-Levodopa | None | 48 | $3,635 | $76 |
| Pyridostigmine | None | 23 | $3,506 | $152 |
| Gabapentin | None | 98 | $3,316 | $34 |
| Pregabalin | None | 56 | $2,504 | $45 |
| Propranolol | None | 45 | $2,180 | $48 |
| Propranolol Hcl Er | None | 11 | $2,045 | $186 |
| Levetiracetam | None | 50 | $1,819 | $36 |
| Armodafinil | None | 12 | $1,740 | $145 |
| Escitalopram | None | 72 | $1,625 | $23 |
| Sumatriptan | None | 37 | $1,570 | $42 |
| Pramipexole Dihydrochloride | None | 17 | $1,021 | $60 |
| Primidone | None | 23 | $945 | $41 |
| Topiramate | None | 34 | $712 | $21 |
| Rizatriptan | None | 11 | $551 | $50 |
| Divalproex | None | 25 | $513 | $21 |
| Atorvastatin | None | 33 | $508 | $15 |
| Clopidogrel | None | 17 | $498 | $29 |
| Hydrocodone-Acetaminophen | None | 15 | $264 | $18 |
| Methadone | None | 12 | $174 | $15 |
| Clonazepam | None | 17 | $170 | $10 |
| Quetiapine | None | 25 | $156 | $6 |
| Sertraline | None | 13 | $146 | $11 |
| Amitriptyline | None | 12 | $88 | $7 |
| Tramadol | None | 15 | $54 | $4 |
2019: 40 drugs
| Hizentra | Immune globulin | 14 | $235,534 | $16,824 |
| Gamunex-C | Immune globulin | 12 | $166,027 | $13,836 |
| Northera | None | 11 | $155,649 | $14,150 |
| Ampyra | None | 12 | $35,284 | $2,940 |
| Nuedexta | None | 18 | $27,565 | $1,531 |
| Rivastigmine | None | 71 | $26,337 | $371 |
| Namzaric | None | 44 | $24,454 | $556 |
| Rasagiline Mesylate | None | 15 | $16,019 | $1,068 |
| Neupro | None | 25 | $15,154 | $606 |
| Lyrica | None | 21 | $14,526 | $692 |
| Aspirin-Dipyridamole Er | None | 12 | $11,299 | $942 |
| Memantine Hcl Er | None | 29 | $10,807 | $373 |
| Memantine | None | 52 | $5,384 | $104 |
| Donepezil | None | 265 | $4,536 | $17 |
| Modafinil | None | 14 | $4,467 | $319 |
| Gabapentin | None | 72 | $4,280 | $59 |
| Tegretol Xr | None | 12 | $3,946 | $329 |
| Riluzole | None | 11 | $3,085 | $280 |
| Carbidopa-Levodopa | None | 51 | $3,032 | $59 |
| Rivastigmine | None | 15 | $1,959 | $131 |
| Levetiracetam | None | 69 | $1,904 | $28 |
| Escitalopram | None | 80 | $1,884 | $24 |
| Propranolol Hcl Er | None | 13 | $1,750 | $135 |
| Divalproex Sodium Er | None | 23 | $1,583 | $69 |
| Pyridostigmine | None | 15 | $1,495 | $100 |
| Propranolol | None | 38 | $1,287 | $34 |
| Pregabalin | None | 27 | $1,002 | $37 |
| Primidone | None | 26 | $972 | $37 |
| Sumatriptan | None | 33 | $955 | $29 |
| Pramipexole Dihydrochloride | None | 31 | $808 | $26 |
| Hydrocodone-Acetaminophen | None | 22 | $724 | $33 |
| Atorvastatin | None | 28 | $559 | $20 |
| Clopidogrel | None | 15 | $468 | $31 |
| Divalproex | None | 21 | $463 | $22 |
| Topiramate | None | 11 | $456 | $41 |
| Amitriptyline | None | 17 | $265 | $16 |
| Tramadol | None | 16 | $181 | $11 |
| Methadone | None | 11 | $173 | $16 |
| Quetiapine | None | 17 | $150 | $9 |
| Clonazepam | None | 18 | $126 | $7 |
2018: 40 drugs
| Gamunex-C | Immune globulin | 12 | $151,194 | $12,599 |
| Namzaric | None | 54 | $34,607 | $641 |
| Ampyra | None | 11 | $30,390 | $2,763 |
| Nuedexta | None | 14 | $29,637 | $2,117 |
| Vimpat | None | 23 | $28,611 | $1,244 |
| Rasagiline Mesylate | None | 22 | $27,240 | $1,238 |
| Rivastigmine | None | 47 | $26,327 | $560 |
| Lyrica | None | 34 | $18,799 | $553 |
| Neupro | None | 19 | $17,438 | $918 |
| Trokendi Xr | None | 16 | $14,574 | $911 |
| Namenda Xr | None | 13 | $12,425 | $956 |
| Aspirin-Dipyridamole Er | None | 16 | $11,952 | $747 |
| Exelon | None | 14 | $9,116 | $651 |
| Memantine Hcl Er | None | 22 | $8,866 | $403 |
| Gralise | None | 11 | $8,763 | $797 |
| Riluzole | None | 11 | $4,622 | $420 |
| Donepezil | None | 218 | $3,699 | $17 |
| Gabapentin | None | 62 | $3,301 | $53 |
| Divalproex Sodium Er | None | 27 | $3,095 | $115 |
| Levetiracetam | None | 60 | $2,180 | $36 |
| Propranolol Hcl Er | None | 12 | $1,971 | $164 |
| Memantine | None | 22 | $1,871 | $85 |
| Carbidopa-Levodopa | None | 49 | $1,817 | $37 |
| Sumatriptan | None | 40 | $1,747 | $44 |
| Pyridostigmine | None | 14 | $1,607 | $115 |
| Escitalopram | None | 97 | $1,585 | $16 |
| Rivastigmine | None | 14 | $1,570 | $112 |
| Propranolol | None | 43 | $1,091 | $25 |
| Hydrocodone-Acetaminophen | None | 17 | $638 | $38 |
| Clopidogrel | None | 14 | $454 | $32 |
| Primidone | None | 20 | $423 | $21 |
| Pramipexole Dihydrochloride | None | 21 | $405 | $19 |
| Atorvastatin | None | 17 | $285 | $17 |
| Divalproex | None | 22 | $224 | $10 |
| Prednisone | None | 16 | $221 | $14 |
| Clonazepam | None | 17 | $205 | $12 |
| Methadone | None | 11 | $116 | $11 |
| Sertraline | None | 14 | $93 | $7 |
| Quetiapine | None | 11 | $51 | $5 |
| Ondansetron | None | 11 | $18 | $2 |
2017: 35 drugs
| Northera | None | 12 | $156,313 | $13,026 |
| Gamunex-C | Immune globulin | 32 | $92,676 | $2,896 |
| Namenda Xr | None | 46 | $32,120 | $698 |
| Rivastigmine | None | 56 | $30,590 | $546 |
| Ampyra | None | 11 | $26,309 | $2,392 |
| Rasagiline Mesylate | None | 23 | $21,342 | $928 |
| Vimpat | None | 15 | $19,725 | $1,315 |
| Lyrica | None | 35 | $18,021 | $515 |
| Aspirin-Dipyridamole Er | None | 21 | $14,289 | $680 |
| Exelon | None | 17 | $13,826 | $813 |
| Azilect | None | 19 | $13,242 | $697 |
| Namzaric | None | 20 | $13,196 | $660 |
| Gralise | None | 20 | $6,610 | $330 |
| Gabapentin | None | 65 | $4,140 | $64 |
| Propranolol Hcl Er | None | 30 | $3,355 | $112 |
| Donepezil | None | 125 | $2,325 | $19 |
| Pyridostigmine | None | 17 | $2,181 | $128 |
| Divalproex Sodium Er | None | 22 | $2,034 | $92 |
| Carbidopa-Levodopa | None | 41 | $1,597 | $39 |
| Levetiracetam | None | 59 | $1,504 | $25 |
| Propranolol | None | 47 | $1,354 | $29 |
| Memantine | None | 14 | $1,209 | $86 |
| Sumatriptan | None | 21 | $1,057 | $50 |
| Escitalopram | None | 68 | $702 | $10 |
| Fenofibrate | None | 11 | $655 | $60 |
| Clopidogrel | None | 21 | $609 | $29 |
| Pramipexole Dihydrochloride | None | 13 | $439 | $34 |
| Primidone | None | 24 | $376 | $16 |
| Clonazepam | None | 16 | $233 | $15 |
| Atorvastatin | None | 18 | $215 | $12 |
| Prednisone | None | 16 | $213 | $13 |
| Levothyroxine | None | 12 | $138 | $12 |
| Sertraline | None | 17 | $132 | $8 |
| Quetiapine | None | 14 | $101 | $7 |
| Ondansetron | None | 12 | $37 | $3 |
2016: 26 drugs
| Rivastigmine | 86 | $38,807 | $451 |
| Namenda Xr | 59 | $30,337 | $514 |
| Ampyra | 12 | $23,574 | $1,965 |
| Nuedexta | 18 | $23,560 | $1,309 |
| Lyrica | 35 | $18,521 | $529 |
| Vimpat | 32 | $17,830 | $557 |
| Aspirin-Dipyridamole Er | 21 | $17,356 | $826 |
| Azilect | 16 | $15,866 | $992 |
| Exelon | 23 | $11,649 | $506 |
| Namzaric | 13 | $6,579 | $506 |
| Gralise | 21 | $6,510 | $310 |
| Gabapentin | 63 | $4,158 | $66 |
| Propranolol Hcl Er | 23 | $2,888 | $126 |
| Donepezil | 118 | $2,650 | $22 |
| Levetiracetam | 61 | $2,247 | $37 |
| Propranolol | 63 | $1,720 | $27 |
| Pramipexole Dihydrochloride | 17 | $957 | $56 |
| Carbidopa-Levodopa | 44 | $947 | $22 |
| Clopidogrel | 26 | $839 | $32 |
| Escitalopram | 51 | $674 | $13 |
| Sumatriptan | 20 | $428 | $21 |
| Primidone | 27 | $331 | $12 |
| Amitriptyline | 18 | $213 | $12 |
| Quetiapine | 23 | $175 | $8 |
| Clonazepam | 17 | $147 | $9 |
| Lorazepam | 17 | $98 | $6 |
2015: 23 drugs
| Copaxone | 11 | $67,762 | $6,160 |
| Exelon | 99 | $48,377 | $489 |
| Lyrica | 46 | $27,170 | $591 |
| Namenda Xr | 54 | $25,133 | $465 |
| Aggrenox | 23 | $17,817 | $775 |
| Rivastigmine | 22 | $8,695 | $395 |
| Gabapentin | 59 | $6,129 | $104 |
| Donepezil | 112 | $5,219 | $47 |
| Propranolol Hcl Er | 15 | $2,857 | $190 |
| Pyridostigmine | 17 | $2,792 | $164 |
| Levetiracetam | 74 | $2,035 | $27 |
| Lidocaine-Prilocaine | 13 | $1,684 | $130 |
| Carbidopa-Levodopa | 61 | $1,233 | $20 |
| Propranolol | 61 | $1,183 | $19 |
| Pramipexole Dihydrochloride | 19 | $956 | $50 |
| Escitalopram | 42 | $484 | $12 |
| Clopidogrel | 23 | $425 | $18 |
| Amitriptyline | 35 | $327 | $9 |
| Quetiapine | 32 | $285 | $9 |
| Lorazepam | 14 | $203 | $15 |
| Sumatriptan | 12 | $134 | $11 |
| Tramadol | 15 | $121 | $8 |
| Clonazepam | 11 | $87 | $8 |
2014: 24 drugs
| Gamunex-C | Immune globulin | 42 | $169,130 | $4,027 |
| Exelon | None | 94 | $38,430 | $409 |
| Namenda Xr | None | 52 | $23,036 | $443 |
| Aggrenox | None | 37 | $20,962 | $567 |
| Lyrica | None | 40 | $18,463 | $462 |
| Namenda | None | 27 | $15,435 | $572 |
| Nuedexta | None | 13 | $14,748 | $1,134 |
| Gabapentin | None | 76 | $12,298 | $162 |
| Donepezil | None | 166 | $9,391 | $57 |
| Levetiracetam | None | 60 | $2,997 | $50 |
| Mycophenolate Mofetil | None | 12 | $2,442 | $203 |
| Pyridostigmine | None | 23 | $2,142 | $93 |
| Pramipexole Dihydrochloride | None | 27 | $1,315 | $49 |
| Carbidopa-Levodopa | None | 36 | $881 | $24 |
| Propranolol | None | 64 | $853 | $13 |
| Lidocaine-Prilocaine | None | 11 | $745 | $68 |
| Escitalopram | None | 30 | $482 | $16 |
| Clopidogrel | None | 14 | $444 | $32 |
| Quetiapine | None | 21 | $439 | $21 |
| Risperidone | None | 11 | $205 | $19 |
| Amitriptyline | None | 33 | $184 | $6 |
| Sertraline | None | 17 | $169 | $10 |
| Tramadol | None | 14 | $159 | $11 |
| Simvastatin | None | 12 | $97 | $8 |
2013: 23 drugs
| Gamunex-C | Immune globulin | 43 | $250,920 | $5,835 |
| Rebif | None | 13 | $56,688 | $4,361 |
| Copaxone | None | 11 | $53,399 | $4,854 |
| Namenda | None | 57 | $27,093 | $475 |
| Aricept | None | 33 | $18,380 | $557 |
| Exelon | None | 42 | $18,048 | $430 |
| Lyrica | None | 49 | $17,582 | $359 |
| Aggrenox | None | 19 | $8,588 | $452 |
| Donepezil | None | 203 | $7,286 | $36 |
| Gabapentin | None | 51 | $5,796 | $114 |
| Levetiracetam | None | 74 | $3,779 | $51 |
| Rivastigmine | None | 13 | $2,477 | $191 |
| Pramipexole Dihydrochloride | None | 30 | $1,926 | $64 |
| Escitalopram | None | 29 | $1,567 | $54 |
| Quetiapine | None | 35 | $1,211 | $35 |
| Oxcarbazepine | None | 14 | $919 | $66 |
| Carbidopa-Levodopa | None | 16 | $623 | $39 |
| Solu-Medrol | None | 45 | $549 | $12 |
| Clopidogrel | None | 18 | $473 | $26 |
| Propranolol | None | 30 | $287 | $10 |
| Tramadol | None | 16 | $286 | $18 |
| Simvastatin | None | 12 | $111 | $9 |
| Amitriptyline | None | 13 | $41 | $3 |
Money from drug and device companies
$73,991 in 2025
| 2025 | 34 | 268 | $58,120 | $73,991 |
| 2024 | 33 | 214 | $30,625 | $39,657 |
| 2023 | 35 | 253 | $32,780 | $39,794 |
| 2022 | 37 | 220 | $31,745 | $38,338 |
| 2021 | 40 | 327 | $42,000 | $50,396 |
| 2020 | 30 | 164 | $14,240 | $17,560 |
| 2019 | 33 | 192 | $15,880 | $22,461 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Argenx US | Vyvgart | $24,241 | 34 payments
|
| Abbvie | Qulipta | $23,100 | 40 payments
|
| Lilly USA | Kisunla | $8,829 | 8 payments
|
| Sarepta Therapeutics | None | $6,456 | 5 payments
|
| Lundbeck | Vyepti | $5,730 | 20 payments
|
| Alexion Pharmaceuticals | Ultomiris | $1,636 | 8 payments
|
See all 268 published payments
| Argenx US | Meals · 2025-12-17 | Vyvgart Hytrulo | $19 |
| Catalyst Pharmaceuticals | Meals · 2025-12-16 | Firdapse | $19 |
| Genzyme | Meals · 2025-12-15 | None | $21 |
| Amgen | Meals · 2025-12-11 | None | $36 |
| Janssen Biotech | Education · 2025-12-10 | None | $99 |
| Lundbeck | Meals · 2025-12-10 | Vyepti | $11 |
| Abbvie | Meals · 2025-12-09 | Qulipta | $16 |
| Teva Pharmaceuticals USA | Meals · 2025-12-09 | Austedo Xr | $29 |
| Neurelis | Meals · 2025-12-08 | Valtoco | $8 |
| Abbvie | Paid to speak or teach · 2025-12-04 | Qulipta | $3,675 |
| Argenx US | Paid to speak or teach · 2025-12-04 | Vyvgart | $1,000 |
| Abbvie | Meals · 2025-12-02 | Qulipta | $7 |
| Janssen Biotech | Meals · 2025-12-01 | None | $35 |
| Alexion Pharmaceuticals | Meals · 2025-11-27 | Ultomiris | $18 |
| Catalyst Pharmaceuticals | Meals · 2025-11-25 | Firdapse | $22 |
| Catalyst Pharmaceuticals | Meals · 2025-11-25 | Firdapse | $9 |
| Lilly USA | Consulting · 2025-11-24 | Kisunla | $6,800 |
| Lilly USA | Consulting · 2025-11-24 | Kisunla | $1,400 |
| Tanabe Pharma America | Meals · 2025-11-24 | None | $18 |
| Abbvie | Travel · 2025-11-20 | Qulipta | $431 |
| Abbvie | Travel · 2025-11-20 | Qulipta | $171 |
| Abbvie | Meals · 2025-11-20 | Qulipta | $125 |
| Abbvie | Travel · 2025-11-20 | Qulipta | $865 |
| Abbvie | Meals · 2025-11-20 | Qulipta | $27 |
| Abbvie | Travel · 2025-11-20 | Qulipta | $205 |
| Argenx US | Paid to speak or teach · 2025-11-20 | Vyvgart | $2,000 |
| Lilly USA | Travel · 2025-11-14 | None | $496 |
| Alexion Pharmaceuticals | Meals · 2025-11-14 | Ultomiris | $35 |
| Pfizer | Meals · 2025-11-13 | Nurtec Odt | $10 |
| Abbvie | Meals · 2025-11-12 | Qulipta | $8 |
| Vanda Pharmaceuticals | Meals · 2025-11-12 | Ponvory | $27 |
| Argenx US | Meals · 2025-11-11 | Vyvgart | $115 |
| Argenx US | Meals · 2025-11-06 | Vyvgart Hytrulo | $24 |
| Eisai | Meals · 2025-11-06 | Leqembi | $15 |
| Ucb | Meals · 2025-10-30 | Nayzilam | $39 |
| Argenx US | Meals · 2025-10-30 | Vyvgart Hytrulo | $150 |
| Janssen Biotech | Meals · 2025-10-28 | None | $27 |
| Janssen Biotech | Meals · 2025-10-28 | None | $7 |
| Ucb | Meals · 2025-10-28 | Rystiggo | $4 |
| Ucb | Meals · 2025-10-28 | Rystiggo | $11 |
| Pfizer | Meals · 2025-10-24 | Nurtec Odt | $8 |
| Grifols USA | Meals · 2025-10-24 | Gamunex-C | $38 |
| Neurocrine BioSciences | Meals · 2025-10-23 | Ingrezza | $15 |
| Jazz Pharmaceuticals | Meals · 2025-10-22 | Epidiolex | $39 |
| Lilly USA | Meals · 2025-10-21 | Kisunla | $28 |
| Abbvie | Meals · 2025-10-20 | Qulipta | $7 |
| Amgen | Meals · 2025-10-17 | Uplizna | $30 |
| Neurocrine BioSciences | Meals · 2025-10-16 | Ingrezza | $14 |
| SK Life Science | Meals · 2025-10-16 | None | $20 |
| SK Life Science | Meals · 2025-10-16 | None | $4 |
| Abbvie | Meals · 2025-10-15 | Botox | $28 |
| Genentech USA | Meals · 2025-10-14 | Ocrevus Zunovo | $30 |
| Eisai | Meals · 2025-10-14 | Leqembi | $125 |
| CSL Behring | Meals · 2025-10-10 | Hizentra | $30 |
| Amgen | Meals · 2025-10-09 | None | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-10-08 | Austedo Xr | $36 |
| Lundbeck | Meals · 2025-10-06 | Vyepti | $29 |
| Pfizer | Meals · 2025-10-03 | Nurtec Odt | $9 |
| Janssen Biotech | Meals · 2025-10-02 | None | $150 |
| Neurelis | Meals · 2025-10-02 | Valtoco | $6 |
| Lundbeck | Meals · 2025-10-02 | Vyepti | $8 |
| Eisai | Meals · 2025-10-01 | Leqembi | $20 |
| Janssen Biotech | Meals · 2025-09-30 | None | $34 |
| Janssen Biotech | Meals · 2025-09-30 | None | $6 |
| Lundbeck | Consulting · 2025-09-30 | Vyepti | $800 |
| Catalyst Pharmaceuticals | Meals · 2025-09-29 | Firdapse | $13 |
| Catalyst Pharmaceuticals | Meals · 2025-09-29 | Firdapse | $26 |
| Catalyst Pharmaceuticals | Meals · 2025-09-29 | Firdapse | $2 |
| Ucb | Meals · 2025-09-26 | Rystiggo | $46 |
| Lilly USA | Meals · 2025-09-24 | Kisunla | $27 |
| TG Therapeutics | Meals · 2025-09-24 | Briumvi | $34 |
| Argenx US | Meals · 2025-09-23 | Vyvgart Hytrulo | $33 |
| Alexion Pharmaceuticals | Meals · 2025-09-19 | Ultomiris | $33 |
| Pfizer | Meals · 2025-09-19 | Nurtec Odt | $10 |
| Alexion Pharmaceuticals | Meals · 2025-09-18 | Ultomiris | $98 |
| Ucb | Meals · 2025-09-18 | Rystiggo | $9 |
| Catalyst Pharmaceuticals | Meals · 2025-09-17 | Firdapse | $26 |
| Catalyst Pharmaceuticals | Meals · 2025-09-17 | Firdapse | $7 |
| Alexion Pharmaceuticals | Consulting · 2025-09-09 | Ultomiris | $1,400 |
| SK Life Science | Meals · 2025-09-09 | None | $24 |
| SK Life Science | Meals · 2025-09-08 | None | $5 |
| SK Life Science | Meals · 2025-09-08 | None | $2 |
| Abbvie | Meals · 2025-09-05 | Botox | $32 |
| Neurocrine BioSciences | Meals · 2025-09-04 | Ingrezza | $34 |
| Catalyst Pharmaceuticals | Meals · 2025-09-04 | Firdapse | $22 |
| Catalyst Pharmaceuticals | Meals · 2025-09-04 | Firdapse | $12 |
| Jazz Pharmaceuticals | Meals · 2025-09-03 | Epidiolex | $21 |
| Lundbeck | Meals · 2025-09-02 | Vyepti | $35 |
| Pfizer | Meals · 2025-08-28 | Nurtec Odt | $28 |
| Catalyst Pharmaceuticals | Meals · 2025-08-28 | Firdapse | $22 |
| Eisai | Meals · 2025-08-27 | Leqembi | $27 |
| Argenx US | Meals · 2025-08-20 | Vyvgart Hytrulo | $32 |
| Ucb | Meals · 2025-08-19 | Nayzilam | $52 |
| Catalyst Pharmaceuticals | Meals · 2025-08-19 | Firdapse | $10 |
| Catalyst Pharmaceuticals | Meals · 2025-08-19 | Firdapse | $17 |
| Axsome Therapeutics | Meals · 2025-08-13 | Symbravo | $33 |
| Genentech USA | Meals · 2025-08-12 | Ocrevus Zunovo | $31 |
| Abbvie | Meals · 2025-08-11 | Botox | $5 |
| Neurelis | Meals · 2025-08-11 | Valtoco | $42 |
| Catalyst Pharmaceuticals | Meals · 2025-08-11 | Firdapse | $20 |
| CSL Behring | Meals · 2025-08-05 | Hizentra | $37 |
| Argenx US | Travel · 2025-08-04 | Vyvgart | $208 |
| Argenx US | Paid to speak or teach · 2025-08-04 | Vyvgart | $3,000 |
| Argenx US | Travel · 2025-08-04 | Vyvgart | $448 |
| Biogen | Meals · 2025-07-29 | Vumerity | $19 |
| Janssen Biotech | Meals · 2025-07-28 | None | $36 |
| Abbvie | Paid to speak or teach · 2025-07-24 | Qulipta | $3,675 |
| Neurelis | Meals · 2025-07-24 | Valtoco | $27 |
| Merz Pharmaceuticals | Meals · 2025-07-23 | Inbrija | $15 |
| Teva Pharmaceuticals USA | Meals · 2025-07-23 | Austedo Xr | $28 |
| Lundbeck | Meals · 2025-07-22 | Vyepti | $9 |
| Catalyst Pharmaceuticals | Meals · 2025-07-22 | Firdapse | $22 |
| Catalyst Pharmaceuticals | Meals · 2025-07-21 | Firdapse | $9 |
| Argenx US | Meals · 2025-07-18 | Vyvgart Hytrulo | $34 |
| Abbvie | Travel · 2025-07-16 | Qulipta | $1,347 |
| Abbvie | Meals · 2025-07-16 | Qulipta | $77 |
| Axsome Therapeutics | Meals · 2025-07-16 | Symbravo | $168 |
| Argenx US | Meals · 2025-07-15 | Vyvgart | $102 |
| Ucb | Meals · 2025-07-10 | Rystiggo | $30 |
| Neurocrine BioSciences | Meals · 2025-07-10 | Ingrezza | $13 |
| Lundbeck | Meals · 2025-07-10 | Vyepti | $10 |
| Pfizer | Meals · 2025-07-09 | Nurtec Odt | $10 |
| Neurocrine BioSciences | Meals · 2025-07-09 | Ingrezza | $35 |
| Eisai | Meals · 2025-07-09 | Leqembi | $26 |
| Lilly USA | Meals · 2025-07-08 | Kisunla | $30 |
| SK Life Science | Meals · 2025-07-03 | None | $32 |
| SK Life Science | Meals · 2025-07-03 | None | $5 |
| Abbvie | Meals · 2025-07-02 | Botox | $4 |
| Abbvie | Paid to speak or teach · 2025-07-02 | Ubrelvy | $3,675 |
| Abbvie | Meals · 2025-07-02 | Botox | $27 |
| Biogen | Meals · 2025-07-02 | Tysabri | $29 |
| Janssen Biotech | Meals · 2025-06-26 | None | $8 |
| Argenx US | Travel · 2025-06-23 | Vyvgart | $295 |
| Argenx US | Meals · 2025-06-23 | Vyvgart | $29 |
| Argenx US | Paid to speak or teach · 2025-06-23 | Vyvgart | $4,000 |
| Abbvie | Travel · 2025-06-19 | Ubrelvy | $970 |
| Neurocrine BioSciences | Meals · 2025-06-19 | Ingrezza | $14 |
| Abbvie | Meals · 2025-06-18 | Ubrelvy | $109 |
| Argenx US | Paid to speak or teach · 2025-06-17 | Vyvgart | $2,000 |
| Argenx US | Travel · 2025-06-17 | Vyvgart | $331 |
| Life Molecular Imaging | Meals · 2025-06-17 | Neuraceq | $8 |
| Otsuka America Pharmaceutical | Meals · 2025-06-16 | Rexulti | $30 |
| Novartis Pharmaceuticals | Meals · 2025-06-15 | Kesimpta | $34 |
| Catalyst Pharmaceuticals | Meals · 2025-06-10 | Firdapse | $5 |
| Catalyst Pharmaceuticals | Meals · 2025-06-10 | Firdapse | $10 |
| Abbvie | Meals · 2025-06-06 | Botox | $31 |
| SK Life Science | Meals · 2025-06-06 | None | $33 |
| Biogen | Meals · 2025-06-04 | Tysabri | $18 |
| Abbvie | Paid to speak or teach · 2025-06-03 | Ubrelvy | $1,575 |
| Argenx US | Paid to speak or teach · 2025-06-03 | Vyvgart | $3,000 |
| Argenx US | Paid to speak or teach · 2025-05-30 | Vyvgart | $750 |
| Ucb | Meals · 2025-05-29 | Briviact | $43 |
| Pfizer | Meals · 2025-05-29 | Nurtec Odt | $27 |
| Neurelis | Meals · 2025-05-27 | Valtoco | $28 |
| Hospira | Meals · 2025-05-22 | Panzyga | $20 |
| Catalyst Pharmaceuticals | Meals · 2025-05-22 | Firdapse | $18 |
| Catalyst Pharmaceuticals | Meals · 2025-05-22 | Firdapse | $12 |
| Eisai | Meals · 2025-05-21 | Leqembi | $29 |
| Novartis Pharmaceuticals | Meals · 2025-05-20 | Kesimpta | $32 |
| Abbvie | Meals · 2025-05-20 | Ubrelvy | $0 |
| Neurocrine BioSciences | Meals · 2025-05-20 | Ingrezza | $11 |
| Lundbeck | Meals · 2025-05-16 | Vyepti | $34 |
| SK Life Science | Meals · 2025-05-16 | None | $30 |
| Argenx US | Meals · 2025-05-14 | Vyvgart | $122 |
| Neurocrine BioSciences | Meals · 2025-05-14 | Ingrezza | $31 |
| Lundbeck | Honoraria · 2025-05-13 | Vyepti | $2,000 |
| Argenx US | Travel · 2025-05-12 | Vyvgart | $293 |
| Argenx US | Travel · 2025-05-12 | Vyvgart | $236 |
| Argenx US | Paid to speak or teach · 2025-05-12 | Vyvgart | $3,000 |
| Argenx US | Travel · 2025-05-12 | Vyvgart | $55 |
| Argenx US | Travel · 2025-05-12 | Vyvgart | $455 |
| Argenx US | Travel · 2025-05-12 | Vyvgart | $324 |
| Argenx US | Meals · 2025-05-12 | Vyvgart | $100 |
| Argenx US | Meals · 2025-05-07 | Vyvgart Hytrulo | $34 |
| SK Life Science | Meals · 2025-05-07 | None | $34 |
| Abbvie | Meals · 2025-05-06 | Qulipta | $29 |
| Merz Pharmaceuticals | Meals · 2025-05-05 | Inbrija | $33 |
| Biogen | Meals · 2025-05-02 | Tysabri | $25 |
| Neurocrine BioSciences | Meals · 2025-05-02 | Ingrezza | $25 |
| Ucb | Meals · 2025-04-30 | Rystiggo | $1 |
| Ucb | Meals · 2025-04-30 | Rystiggo | $13 |
| Teva Pharmaceuticals USA | Meals · 2025-04-30 | Austedo Xr | $32 |
| Celgene | Meals · 2025-04-28 | Zeposia | $18 |
| Biogen | Meals · 2025-04-28 | Tysabri | $17 |
| Argenx US | Meals · 2025-04-27 | Vyvgart | $125 |
| Argenx US | Paid to speak or teach · 2025-04-25 | None | $1,750 |
| Lundbeck | Meals · 2025-04-25 | Vyepti | $22 |
| Lundbeck | Meals · 2025-04-25 | Vyepti | $2 |
| Lundbeck | Meals · 2025-04-25 | Vyepti | $1 |
| Lundbeck | Meals · 2025-04-25 | Vyepti | $0 |
| Lundbeck | Travel · 2025-04-25 | Vyepti | $540 |
| SK Life Science | Meals · 2025-04-24 | None | $31 |
| Genentech USA | Meals · 2025-04-23 | Ocrevus Zunovo | $15 |
| Otsuka America Pharmaceutical | Meals · 2025-04-23 | Rexulti | $23 |
| Alexion Pharmaceuticals | Meals · 2025-04-22 | Ultomiris | $6 |
| Alexion Pharmaceuticals | Meals · 2025-04-22 | Ultomiris | $25 |
| Pfizer | Meals · 2025-04-22 | Nurtec Odt | $29 |
| Lundbeck | Travel · 2025-04-22 | Vyepti | $40 |
| Abbvie | Paid to speak or teach · 2025-04-18 | Ubrelvy | $2,625 |
| Neurocrine BioSciences | Meals · 2025-04-18 | Ingrezza | $35 |
| Sarepta Therapeutics | Consulting · 2025-04-17 | None | $5,270 |
| Argenx US | Meals · 2025-04-16 | Vyvgart | $125 |
| Biogen | Meals · 2025-04-14 | Tysabri | $0 |
| Biogen | Meals · 2025-04-11 | Skyclarys | $29 |
| Celgene | Meals · 2025-04-10 | Zeposia | $20 |
| Abbvie | Meals · 2025-04-09 | Qulipta | $17 |
| Abbvie | Paid to speak or teach · 2025-04-07 | Qulipta | $2,625 |
| Sarepta Therapeutics | Meals · 2025-04-04 | None | $45 |
| Sarepta Therapeutics | Travel · 2025-04-04 | None | $234 |
| Sarepta Therapeutics | Travel · 2025-04-04 | None | $303 |
| Sarepta Therapeutics | Travel · 2025-04-04 | None | $604 |
| Eisai | Meals · 2025-04-03 | Leqembi | $30 |
| Neurocrine BioSciences | Meals · 2025-04-02 | Ingrezza | $23 |
| Neurocrine BioSciences | Meals · 2025-04-02 | Ingrezza | $1 |
| Lundbeck | Meals · 2025-04-01 | Vyepti | $35 |
| Catalyst Pharmaceuticals | Meals · 2025-03-31 | Fycompa | $8 |
| Catalyst Pharmaceuticals | Meals · 2025-03-31 | Fycompa | $14 |
| Neurocrine BioSciences | Meals · 2025-03-29 | Ingrezza | $12 |
| Argenx US | Meals · 2025-03-28 | Vyvgart Hytrulo | $34 |
| Abbvie | Travel · 2025-03-27 | Ubrelvy | $272 |
| Abbvie | Meals · 2025-03-27 | Ubrelvy | $124 |
| Abbvie | Meals · 2025-03-26 | Ubrelvy | $18 |
| Neurelis | Meals · 2025-03-26 | Valtoco | $47 |
| Ucb | Meals · 2025-03-26 | Briviact | $45 |
| Abbvie | Meals · 2025-03-19 | Ubrelvy | $19 |
| Biogen | Meals · 2025-03-19 | Skyclarys | $26 |
| Otsuka America Pharmaceutical | Meals · 2025-03-19 | Rexulti | $30 |
| Neurocrine BioSciences | Meals · 2025-03-14 | Ingrezza | $36 |
| Abbvie | Travel · 2025-03-12 | Qulipta | $42 |
| Abbvie | Meals · 2025-03-12 | Qulipta | $125 |
| Ucb | Meals · 2025-03-12 | Rystiggo | $14 |
| Teva Pharmaceuticals USA | Education · 2025-03-12 | None | $91 |
| Teva Pharmaceuticals USA | Meals · 2025-03-12 | Austedo Xr | $37 |
| Pfizer | Meals · 2025-03-11 | Nurtec Odt | $22 |
| Biogen | Meals · 2025-03-05 | Tysabri | $18 |
| Genentech USA | Meals · 2025-03-05 | Ocrevus Zunovo | $31 |
| Abbvie | Meals · 2025-03-03 | Ubrelvy | $19 |
| SK Life Science | Meals · 2025-03-03 | None | $22 |
| Lilly USA | Meals · 2025-02-27 | Kisunla | $26 |
| Abbvie | Meals · 2025-02-26 | Qulipta | $28 |
| Eisai | Meals · 2025-02-25 | Leqembi | $34 |
| Lundbeck | Meals · 2025-02-25 | Vyepti | $17 |
| Lundbeck | Meals · 2025-02-25 | Vyepti | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-24 | Hyqvia | $23 |
| Neurelis | Meals · 2025-02-19 | Valtoco | $36 |
| Eisai | Meals · 2025-02-19 | Leqembi | $125 |
| Hospira | Meals · 2025-02-18 | Octagam Immune Globulin (Human) | $21 |
| Neurocrine BioSciences | Meals · 2025-02-13 | Ingrezza | $24 |
| Lilly USA | Meals · 2025-02-06 | Kisunla | $22 |
| Abbvie | Meals · 2025-02-04 | Ubrelvy | $23 |
| Biogen | Meals · 2025-01-30 | Avonex | $11 |
| Neurocrine BioSciences | Meals · 2025-01-30 | Ingrezza | $7 |
| Catalyst Pharmaceuticals | Meals · 2025-01-30 | Fycompa | $15 |
| Alexion Pharmaceuticals | Meals · 2025-01-29 | Ultomiris | $22 |
| Argenx US | Meals · 2025-01-29 | Vyvgart Hytrulo | $19 |
| Abbvie | Meals · 2025-01-22 | Ubrelvy | $24 |
| Amgen | Meals · 2025-01-22 | Uplizna | $33 |
| Lundbeck | Meals · 2025-01-18 | Vyepti | $34 |
| Neurocrine BioSciences | Meals · 2025-01-17 | Ingrezza | $25 |
| Teva Pharmaceuticals USA | Meals · 2025-01-16 | Ajovy | $4 |
| Teva Pharmaceuticals USA | Meals · 2025-01-16 | Ajovy | $9 |
| Biogen | Meals · 2025-01-15 | Tysabri | $30 |
| Catalyst Pharmaceuticals | Meals · 2025-01-10 | Fycompa | $10 |
| Catalyst Pharmaceuticals | Meals · 2025-01-10 | Fycompa | $11 |
| Eisai | Meals · 2025-01-09 | Leqembi | $25 |
| Harmony Biosciences | Meals · 2025-01-08 | Wakix | $36 |
| Lundbeck | Honoraria · 2025-01-07 | Vyepti | $2,100 |
| Abbvie | Meals · 2025-01-06 | Ubrelvy | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $39,657
| Abbvie | Qulipta | $29,771 | 52 payments
|
| Lundbeck | Vyepti | $6,159 | 21 payments
|
| Lilly USA | Kisunla | $395 | 13 payments
|
| Alexion Pharmaceuticals | Ultomiris | $319 | 10 payments
|
| Novartis Pharmaceuticals | Kesimpta | $278 | 7 payments
|
| SK Life Science | Xcopri | $249 | 10 payments
|
| Ucb | Briviact | $245 | 7 payments
|
| Neurelis | Valtoco | $235 | 8 payments
|
| Argenx US | Vyvgart Hytrulo | $228 | 9 payments
|
| Biogen | Tysabri | $205 | 10 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $181 | 7 payments
|
| Pfizer | Nurtec Odt | $177 | 8 payments
|
| Catalyst Pharmaceuticals | Fycompa | $168 | 11 payments
|
| Eisai | Leqembi | $125 | 6 payments
|
| Amgen | Uplizna | $108 | 4 payments
|
| CSL Behring | Hizentra | $92 | 3 payments
|
| Octapharma USA | Panzyga | $81 | 2 payments
|
| Acorda Therapeutics | Inbrija | $79 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Hyqvia | $75 | 3 payments
|
| Hospira | Panzyga | $65 | 4 payments
|
| EMD Serono | None | $65 | 2 payments
|
| Celgene | Zeposia | $62 | 3 payments
|
| Harmony Biosciences | Wakix | $39 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $36 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $31 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $31 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $29 | 1 payment
|
| Sumitomo Pharma America | Aptiom | $29 | 1 payment
|
| Kyowa Kirin | Nourianz | $23 | 1 payment
|
| Otsuka America Pharmaceutical | Nuedexta | $23 | 1 payment
|
| Banner Life Sciences | Bafiertam | $19 | 1 payment
|
| Genentech USA | Ocrevus | $19 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $18 | 1 payment
|
2023: $39,794
| AbbVie | Qulipta | $27,546 | 35 payments
|
| Argenx US | Vyvgart | $6,617 | 13 payments
|
| Alexion Pharmaceuticals | Ultomiris | $2,165 | 11 payments
|
| Biogen | Tysabri | $349 | 15 payments
|
| Impel Pharmaceuticals | Trudhesa | $324 | 26 payments
|
| SK Life Science | None | $285 | 23 payments
|
| Ucb | Briviact | $241 | 7 payments
|
| Sumitomo Pharma America | Aptiom | $214 | 14 payments
|
| Neurocrine Biosciences | Ongentys | $201 | 9 payments
|
| Lilly USA | Amyvid | $187 | 12 payments
|
| Lundbeck | Vyepti | $173 | 12 payments
|
| Genentech USA | Enspryng | $167 | 10 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $164 | 8 payments
|
| Horizon Therapeutics plc | Uplizna | $140 | 8 payments
|
| Acorda Therapeutics | Inbrija | $121 | 6 payments
|
| Pfizer | Nurtec Odt | $108 | 6 payments
|
| Hospira | Octagam Immune Globulin (Human) | $78 | 6 payments
|
| Otsuka America Pharmaceutical | Rexulti | $68 | 3 payments
|
| MDD US Operations | None | $66 | 3 payments
|
| Harmony Biosciences | Wakix | $63 | 2 payments
|
| Neurelis | Valtoco | $56 | 2 payments
|
| Mitsubishi Tanabe Pharma America | Radicava | $55 | 2 payments
|
| CSL Behring | Hizentra | $54 | 2 payments
|
| Octapharma USA | Panzyga | $49 | 2 payments
|
| Eisai | Leqembi | $45 | 2 payments
|
| Alnylam Pharmaceuticals | Onpattro | $44 | 2 payments
|
| EMD Serono | Mavenclad | $39 | 2 payments
|
| Janssen Pharmaceuticals | Ponvory | $31 | 1 payment
|
| Catalyst Pharmaceuticals | Fycompa | $29 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Gammagard | $29 | 1 payment
|
| Grifols USA | Gamunex-C | $27 | 1 payment
|
| Life Molecular Imaging | Neuraceq | $18 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $15 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $14 | 1 payment
|
| Kyowa Kirin | Nourianz | $13 | 1 payment
|
2022: $38,338
| Abbvie | Ubrelvy | $22,644 | 41 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $5,665 | 9 payments
|
| Alexion Pharmaceuticals | Ultomiris | $3,837 | 13 payments
|
| Teva Pharmaceuticals USA | Ajovy | $3,112 | 8 payments
|
| Amgen | Aimovig | $600 | 1 payment
|
| Janssen Pharmaceuticals | Ponvory | $525 | 21 payments
|
| SK Life Science | None | $308 | 31 payments
|
| Biogen | Tysabri | $218 | 12 payments
|
| Eisai | Fycompa | $182 | 13 payments
|
| Horizon Therapeutics plc | Uplizna | $176 | 12 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $160 | 13 payments
|
| Neurelis | Valtoco | $72 | 3 payments
|
| Alnylam Pharmaceuticals | Onpattro | $54 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $52 | 3 payments
|
| Harmony Biosciences | Wakix | $51 | 2 payments
|
| Kyowa Kirin | Nourianz | $49 | 3 payments
|
| Supernus Pharmaceuticals | Trokendi Xr | $48 | 2 payments
|
| Lilly USA | Amyvid | $47 | 2 payments
|
| Lundbeck | Vyepti | $40 | 3 payments
|
| Upsher-Smith Laboratories | Zembrace Symtouch | $40 | 2 payments
|
| Acorda Therapeutics | Inbrija | $40 | 2 payments
|
| EMD Serono | None | $38 | 2 payments
|
| Argenx US | Vyvgart | $34 | 1 payment
|
| Alfasigma USA | None | $34 | 1 payment
|
| Genzyme | Aubagio | $34 | 2 payments
|
| Mitsubishi Tanabe Pharma America | Radicava | $30 | 1 payment
|
| Allergan | Botox | $28 | 1 payment
|
| Life Molecular Imaging | Neuraceq | $27 | 2 payments
|
| Genentech USA | Enspryng | $26 | 1 payment
|
| Hospira | Octagam Immune Globulin (Human) | $26 | 1 payment
|
| GRT US Holding | Qutenza | $25 | 1 payment
|
| CSL Behring | Hizentra | $23 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $21 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $21 | 1 payment
|
| Exeltis USA | Purified Cortrophin Gel | $21 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $19 | 1 payment
|
| Ucb | Briviact | $14 | 1 payment
|
2021: $50,396
| Biohaven Pharmaceuticals | Nurtec Odt | $17,123 | 28 payments
|
| AbbVie | Ubrelvy | $14,681 | 30 payments
|
| Teva Pharmaceuticals USA | Ajovy | $11,546 | 27 payments
|
| Amgen | Aimovig | $2,626 | 11 payments
|
| Alexion Pharmaceuticals | Soliris | $783 | 19 payments
|
| Ucb | Vimpat | $530 | 25 payments
|
| Allergan | Ubrelvy | $522 | 20 payments
|
| Eisai | Fycompa | $382 | 39 payments
|
| SK Life Science | None | $243 | 23 payments
|
| Biogen | Tysabri | $239 | 13 payments
|
| Novartis Pharmaceuticals | Kesimpta | $209 | 12 payments
|
| Lundbeck | Vyepti | $144 | 11 payments
|
| Kyowa Kirin | Nourianz | $121 | 8 payments
|
| Sunovion Pharmaceuticals | Aptiom | $121 | 8 payments
|
| Neurocrine Biosciences | Ingrezza | $117 | 6 payments
|
| Horizon Therapeutics plc | Uplizna | $101 | 1 payment
|
| Harmony Biosciences | Wakix | $89 | 3 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $84 | 4 payments
|
| Janssen Pharmaceuticals | Ponvory | $81 | 4 payments
|
| Banner Life Sciences | Bafiertam | $76 | 4 payments
|
| Upsher-Smith Laboratories | Tosymra | $63 | 3 payments
|
| Avanir Pharmaceuticals | Nuedexta | $60 | 3 payments
|
| Pfizer | Panzyga | $51 | 2 payments
|
| CSL Behring | Hizentra | $49 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $35 | 2 payments
|
| Genentech USA | Ocrevus | $32 | 2 payments
|
| Sanofi-Aventis U.S. | Aubagio | $30 | 2 payments
|
| Supernus Pharmaceuticals | Trokendi Xr | $30 | 2 payments
|
| EMD Serono | None | $26 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $25 | 1 payment
|
| Jazz Pharmaceuticals | Xywav | $24 | 1 payment
|
| Ge Healthcare | None | $23 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $22 | 1 payment
|
| Almatica Pharma | Naprelan | $21 | 1 payment
|
| Chiesi USA | Cleviprex | $18 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $17 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $16 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $15 | 1 payment
|
| Adamas Pharmaceuticals | Gocovri | $13 | 1 payment
|
| Life Molecular Imaging | Neuraceq | $9 | 1 payment
|
2020: $17,560
| Amgen | Aimovig | $6,404 | 13 payments
|
| Teva Pharmaceuticals USA | Ajovy | $5,541 | 15 payments
|
| Allergan | Ubrelvy | $1,936 | 25 payments
|
| Alexion Pharmaceuticals | Soliris | $1,780 | 14 payments
|
| Ucb | Vimpat | $327 | 14 payments
|
| Eisai | Fycompa | $229 | 14 payments
|
| Avanir Pharmaceuticals | Nuedexta | $153 | 9 payments
|
| Biogen | Tysabri | $147 | 9 payments
|
| SK Life Science | None | $134 | 9 payments
|
| EMD Serono | Mavenclad | $126 | 8 payments
|
| Harmony Biosciences | Wakix | $122 | 1 payment
|
| Genentech USA | Ocrevus | $67 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $56 | 3 payments
|
| Supernus Pharmaceuticals | Trokendi Xr | $54 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $48 | 2 payments
|
| Lilly USA | Emgality | $45 | 2 payments
|
| Kyowa Kirin | Nourianz | $45 | 3 payments
|
| Novartis Pharmaceuticals | Kesimpta | $45 | 2 payments
|
| US WorldMeds | Apokyn | $42 | 2 payments
|
| Upsher-Smith Laboratories | Tosymra Sumatriptan Nasal Spray | $39 | 2 payments
|
| Lundbeck | Northera | $38 | 2 payments
|
| Akcea Therapeutics | Tegsedi | $29 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $29 | 1 payment
|
| LivaNova USA | Vns Therapy | $28 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $22 | 1 payment
|
| Celgene | Zeposia | $20 | 1 payment
|
| Chiesi USA | Cleviprex 50mg/100ml | $17 | 1 payment
|
| EDW Pharma | Tiglutik | $16 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $12 | 1 payment
|
| Assertio Therapeutics | Cambia | $12 | 1 payment
|
2019: $22,461
| Amgen | Aimovig | $15,443 | 23 payments
|
| Alexion Pharmaceuticals | Soliris | $3,440 | 21 payments
|
| Novartis Pharmaceuticals | Mayzent | $498 | 9 payments
|
| Ucb | Neupro | $414 | 15 payments
|
| Eisai | Fycompa | $295 | 14 payments
|
| Allergan | Botox | $254 | 12 payments
|
| Genentech USA | Ocrevus | $241 | 6 payments
|
| Biogen | Tysabri | $223 | 15 payments
|
| Akcea Therapeutics | Tegsedi | $203 | 4 payments
|
| Amneal Pharmaceuticals | Rytary | $174 | 5 payments
|
| EMD Serono | Mavenclad | $126 | 8 payments
|
| Genzyme | Aubagio | $109 | 5 payments
|
| Bausch Health US | Migranal | $100 | 6 payments
|
| CSL Behring | Hizentra | $78 | 4 payments
|
| Adamas Pharmaceuticals | Gocovri | $77 | 3 payments
|
| US WorldMeds | Xadago | $71 | 4 payments
|
| Portola Pharmaceuticals | Andexxa | $70 | 3 payments
|
| Avanir Pharmaceuticals | Nuedexta | $67 | 3 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $60 | 3 payments
|
| Lundbeck | Northera | $56 | 3 payments
|
| Vertical Pharmaceuticals | Osmolex Er | $53 | 3 payments
|
| Teva Pharmaceuticals USA | Ajovy | $49 | 1 payment
|
| TerSera Therapeutics | Prialt | $47 | 2 payments
|
| Merz North America | Xeomin | $46 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $41 | 2 payments
|
| Sunovion Pharmaceuticals | Aptiom | $41 | 6 payments
|
| Supernus Pharmaceuticals | Oxtellar Xr | $36 | 2 payments
|
| Catalyst Pharmaceuticals | Firdapse | $30 | 1 payment
|
| Lilly USA | Emgality | $29 | 2 payments
|
| Chiesi USA | Cleviprex | $28 | 2 payments
|
| Mallinckrodt Enterprises | Acthar | $24 | 1 payment
|
| Pfizer | Lyrica | $21 | 1 payment
|
| AbbVie | Duopa | $18 | 1 payment
|
Checkups this office reported
16 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 87.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 68%That's more than half. | 324 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 53%That's more than half. | 64 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 0%That's few of the people this applied to. Better on this measure. | 49 |
| Breast cancer screeningEligible women who got a mammogram | 26%That's less than half. | 159 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 15%That's few of the people this applied to. | 184 |
| Checked for fall riskOlder patients screened for fall risk | 4%That's few of the people this applied to. | 336 |
| Colon cancer screeningEligible adults who got a colon cancer test | 18%That's few of the people this applied to. | 305 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 2%That's few of the people this applied to. | 547 |
See the other 8 measures
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 5%That's few of the people this applied to. | 22 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 86%That's most of the people this applied to. Worse on this measure. | 22 |
| HIV screeningEligible patients who were screened for HIV | 13%That's few of the people this applied to. | 335 |
| Medications listed in the chartVisits where the current medication list was documented | 32%That's less than half. | 1,223 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 401 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 94%That's most of the people this applied to. | 559 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 67%That's more than half. | 210 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 32%That's less than half. | 656 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Improved the patient portal
- Lets patients read their visit notes
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
Professional record
- NPI
- 1710141072
- Licence
- CA A104845California A104845: Current · expires 2028-07-31
- Trained
- University of Southern California Keck School of Medicine, 2003
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 2520 Samaritan Dr Ste 201b, San Jose, CA, 95124
- NPI first listed
- 2008-07-16
- NPI last updated
- 2025-02-27
- NPI record certified
- 2025-02-27
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2577 Samaritan Drive, San Jose, CA, 95124